




Research in the field of Abnormal Uterine Bleeding – Where Do We Go?


Joseph Stanco, FNP-BC, CCRC

Women excluded from Clinical Trials




1977

FDA banned women of
childbearing age



1993


NIH mandated inclusion *




2010

2/3 studies exclude
women

Proportion of women in Heart Failure Trials



Is study population representative of those with disease or condition in wider population?



8



*out of 10 medications withdrawn
from market pose more of a
threat for women*

Sex as a Biological Variable (SABV)



January 2016: Implementation of NIH's SABV policy

SABV will factor in all NIH funded studies research designs, analyses, and reporting

Identify sex differences in the presentation, risk factors, and pathophysiology

Animal models should consider if and how the female estrous cycle is relevant for experimental design and analysis


Applicants must provide strong justification for applications proposing to study only one sex




Northwell HTC

Closing the Gap

Regional HTC Network



Regional HTC Network





EQUIPT

Evaluating Quality of life In Period Treatment

lignant



- Effectiveness of hormonal therapy, antifibrinolytic therapy, and intrauterine devices in the treatment of heavy menstrual bleeding (HMB) in adolescent females with an underlying bleeding disorder
- To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency.

- Participants will fill out a demographics




COMBATT-HMB

COMbination therapy in Adolescents To Treat Heavy Menstrual Bleeding





- ATHN-affiliated HTCs document genetic data on the population of rare bleeding disorders
- Assessment of efficacy and safety of tranexamic acid and CHCs in bleeding disorder patients
- Provide baseline data



ROTEM-HMB

Exploring the use of ROTEM and TG Assay in Diagnosing Bleeding disorders in Adolescent Girls with HMB




Parameter (units)	Definition	Treatment
CT _(s)	Thrombin Generation	FFP / PCC
CFT _(s) , α – angle _(degree) , A10 _(degree)	Clot Propagation	Platelets or Cryoprecipitate or both
MCF _(mm)	Clot Strength	Platelets
ML _(%)	Clot Lysis	Anti-fibrinolytics




Long-acting reversible contraceptives (LARC)

Parental Biases on LARC for treatment of Abnormal Uterine Bleeding in the pediatric and adolescent population

- Discover biases that parents hold against LARC
- Improve providers ability to counsel patients' parents on available treatments
- Survey distributed over 2 years
- Published




Digital Data Collection



Better Data Quality




Time Saving



Cost Effective



Stored Securely



Easier to Manage



Your partnership



Distrust

Distrust of
clinical trials



Engage

Engage your
diverse
community in
your practice





Better data leads to better care
Thank you!



<https://www.northwell.edu/clinical-trials>

